Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00148551
Verified July 2007 by Canadian Retinal Trials Group. Recruitment status was: Active, not recruiting
A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.
Condition or disease
Age-Related Macular Degeneration
Drug: Triamcinolone Acetonide
Phase 2Phase 3
This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
50 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Individuals with predominantly classic, subfoveal CNV secondary to AMD.
No previous PDT Treatment in study eye.
CNV from conditions, other than AMD.
Other disease that could be responsible for decreased vision.